Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 66.7 kDa. The protein migrates as 100-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human IL-6 R alpha, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human IL-6, premium grade (Cat. No. IL6-H4218) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha, Fc,Avitag (Cat. No. ILR-H82F9) with a linear range of 0.3-20 ng/mL (QC tested).
Immobilized Human gp130, His Tag (Cat. No. ILT-H52H2) at 5 μg/mL (100 μL/well) can bind Human IL-6, premium grade (Cat. No. IL6-H4218) in the presence of Biotinylated Human IL-6 R alpha, Fc,Avitag (Cat. No. ILR-H82F9) with a linear range of 0.6-20 ng/mL (Routinely tested).
Price(EUR) : €350.00
Price(EUR) : €1540.00
Price(EUR) : €30.00
Price(EUR) : €140.00
Price(EUR) : €50.00
Price(EUR) : €120.00
Price(EUR) : €140.00
Price(EUR) : €230.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tocilizumab | rhPM-1; RO-48775533; RG-1569; MRA; HPM-1; MRA-SC; R-1569 | Approved | Chugai Pharmaceutical Co Ltd | Actemra, RoActemra, 雅美罗, Actemra/RoActemra, Acterma | Japan | Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD); Arthritis, Juvenile | null | 2005-04-11 | Uveitis, Posterior; Polymyalgia Rheumatica; Takayasu Arteritis; Multicentric Castleman's Disease (MCD); systemic sclerosis-associated interstitial lung disease; Breast Neoplasms; Coronavirus Infections; Lupus Erythematosus, Systemic; Coronary Disease; Pulmonary Arterial Hypertension; Fever; Coronaviridae Infections; Lymphoma; Pleural Effusion, Malignant; Stroke; Inflammation; Rejection in heart transplantation; Pulmonary Disease, Chronic Obstructive; Uveitis; Osteoarthritis; Panuveitis; Non-ST Elevated Myocardial Infarction; Carcinoma, Hepatocellular; Anemia, Sickle Cell; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Kidney Failure, Chronic; Myocardial Infarction; Solid tumours; Non-radiographic axial spondyloarthritis; Cytokine Release Syndrome; HIV Infections; Acute Chest Syndrome; Diabetes Mellitus, Type 1; Craniopharyngioma; Motor Neuron Disease; Polymyositis; Schnitzler Syndrome; Giant Cell Arteritis; Uveitis, Intermediate; Pneumonia; Hematologic Neoplasms; Polyarticular Juvenile Idi | Details |
Tocilizumab biosimilar (Bio-Thera Solutions) | BAT-1806; BIIB-800 | Approved | Bio-Thera Solutions Ltd | 施瑞立, TOFIDENCE | Mainland China | Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome | Bio-Thera Solutions Ltd | 2023-01-16 | Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Arthritis, Juvenile | Details |
Satralizumab | RG-6168; SA-237 | Approved | Chugai Pharmaceutical Co Ltd | Enspryng, エンスプリング | Japan | Neuromyelitis Optica | Chugai Pharmaceutical Co Ltd | 2020-06-29 | Myasthenia Gravis; Brain Ischemia; Graves Ophthalmopathy; Neuromyelitis Optica; Pulmonary Arterial Hypertension; Encephalitis; Subarachnoid Hemorrhage; Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Details |
Sarilumab | SAR-153191; REGN-88 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | Kevzara | United States | Arthritis, Rheumatoid | Sanofi-Synthelabo | 2017-05-22 | Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Sarcoidosis; Mastocytosis, Systemic; Arthritis, Juvenile; Polymyalgia Rheumatica; Severe Acute Respiratory Syndrome; Uveitis | Details |
Tocilizumab biosimilar (Livzon Group) | LZM-008 | Approved | Livzon Pharmaceutical Group Inc | 安维泰 | Mainland China | Arthritis, Rheumatoid | Livzon Mabpharm Inc | 2023-01-18 | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (Fresenius kabi) | MSB-11456 | Approved | Merck Serono | Tyenne® | EU | Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis; Coronavirus Disease 2019 (COVID-19) | Fresenius Kabi Deutschland Gmbh | 2023-09-15 | Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant humanized anti-IL-6R antibody (Hisun Pharma) | HS-628 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
Tocilizumab biosimilar (AryoGen Pharmed) | Phase 3 Clinical | Aryogen Biopharma | Arthritis, Rheumatoid | Details | |
CMAB806 | CMAB-806 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Arthritis, Rheumatoid; Arthritis | Details |
Levilimab | BCD-089 | Phase 3 Clinical | Biocad | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) | Details |
Olamkicept | FE-999301; CR-5/18; TJ-301; FE-301 | Phase 2 Clinical | Conaris Research Institute | Colitis, Ulcerative | Details |
Atexakin alfa | SON-080; r-IL-6 | Phase 2 Clinical | Weizmann Institute Of Science | Peripheral Nervous System Diseases; Diabetic Neuropathies | Details |
VDJ-001 | Phase 2 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) | Details | |
Tocilizumab Biosimilar (qyuns) | QX-003-S | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Arthritis, Rheumatoid | Details |
Tocilizumab Biosimilar (Destiny) | IA-001; IA001 | Phase 1 Clinical | Shanghai Destiny Biotech Co Ltd | Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.